2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Outstanding mix of clinical abstracts, including clinical trials, retrospective analysis, and molecular observations in myelofibrosis, polycythemia vera, essential thrombocythemia and other myeloid neoplasms
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric
PAPER

2033 Portal vein thrombosis is associated with increased mortality, recurrent thrombosis, and major bleeding in patients with myeloproliferative neoplasms: A propensity-matched analysis of a multicenter real-world database

Krishna Vasipalli, MD, Efan Jawad, MD2, Nishanth Thalambedu, MD3, Krishna Venkata4
1 UT Health Science Center at SanAntonio, San Antonio, United States
2 UT Health Science Center at SanAntonio, San Antonio, United States
3 University of Arkansas for Medical Sciences, Little Rock, United States
4 Texas Liver Institute, San Antonio, United States

Background

Portal vein thrombosis (PVT) is a well-recognized complication of myeloproliferative neoplasms (MPNs), occurring in the setting of JAK2V617F-driven hypercoagulability. However, existing data on whether PVT independently worsens survival in MPN patients are conflicting: some registry studies report similar or even favorable survival in MPN-associated splanchnic vein thrombosis compared with MPN alone, attributed to earlier disease detection, while population-level data on unselected splanchnic vein thrombosis suggest substantially elevated mortality. We used a large multicenter real-world database to evaluate the association between PVT and clinical outcomes in patients with MPN.

Methods

We performed a retrospective cohort study using the TriNetX Research Network (161.8 million patients, 116 contributing healthcare organizations). Adults ≥18 years with a diagnosis of MPN (ICD-10 D45 polycythemia vera, D47.1 chronic myeloproliferative disease, C94.6, or ICD-O 9962/3 essential thrombocythemia) between January 2015 and January 2025 were identified and stratified by presence or absence of a PVT diagnosis (ICD-10 I81) occurring within 1 year on or after MPN diagnosis. Cohorts were balanced using 1:1 propensity score matching on age, sex, race/ethnicity, and baseline comorbidity categories, yielding 1,224 matched pairs (standardized mean differences <0.05 for all matched covariates). Outcomes over 1 year of follow-up included all-cause mortality (primary), recurrent thrombosis, and major bleeding. Kaplan-Meier analysis with log-rank testing and Cox proportional hazards models were used to compare cohorts; risk ratios and odds ratios were also calculated.

Results

Among 1,224 propensity-matched pairs, MPN patients with PVT had significantly higher 1-year all-cause mortality than those without PVT (12.0% vs. 6.5%; hazard ratio [HR] 0.50, 95% CI 0.38–0.66, favoring the no-PVT cohort; log-rank p<0.001), corresponding to a risk ratio of 1.86 for the PVT cohort. One-year survival probability was 87.2% in the PVT cohort versus 93.2% in the no-PVT cohort.

Recurrent thrombosis was markedly more common in the PVT cohort (47.2% vs. 10.0%; HR 0.15, 95% CI 0.13–0.19; p<0.001). Major bleeding was also significantly increased (15.9% vs. 4.0%; HR 0.22, 95% CI 0.16–0.30; p<0.001). Among patients who experienced recurrent thrombotic events, the mean number of events per patient did not differ significantly between cohorts (5.99 vs. 5.22, p=0.33), suggesting the effect of PVT is primarily on incidence rather than event frequency once thrombosis recurs.  

Conclusion

In this large, propensity-matched, real-world cohort of adults with MPN, PVT was independently associated with a near-doubling of 1-year mortality and substantially higher rates of recurrent thrombosis and major bleeding. These findings support closer surveillance, aggressive thromboprophylaxis, and multidisciplinary hepatology-hematology co-management for MPN patients who develop PVT. Our results diverge from some prior smaller cohorts suggesting that survival in MPN-associated splanchnic vein thrombosis is driven primarily by underlying MPN progression rather than the thrombotic event itself; this discrepancy may reflect differences in matching granularity (our analysis did not incorporate MPN subtype, driver mutation status, or IPSS/DIPSS risk score) and warrants confirmation in cohorts with more detailed disease-risk adjustment.

Krishna Vasipalli, MD: No relevant conflicts of interest to declare.